pharmaceutical investing BioSyent to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference
pharmaceutical investing BioSyent Schedules Fourth Quarter and Full Year 2025 Earnings Release for March 19, 2026
EraNova Announces Positive Preliminary Economic Assessment for the Adanac Molybdenum Project: After-Tax NPV of $714.4 Million and 23.5% IRR